Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Next Previous
Search
Trial Profile

Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Poly ICLC (Primary) ; Cancer vaccine NY-ESO-1; Keyhole limpet haemocyanin; Keyhole limpet haemocyanin; Melanoma vaccine MART-1; Montanide ISA-51
  • Indications Malignant melanoma
  • Focus Pharmacodynamics

    • Most Recent Events

    • 13 Sep 2022 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
    • 23 Oct 2020 Planned End Date changed from 1 Dec 2020 to 1 Oct 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top